We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva (VEEV) announces the availability of Vault Basics for biotechs, which aims to deliver complete and pre-validated solutions for expanding businesses.
BD's (BDX) receipt of the FDA's clearance for the use of self-collected vaginal specimens for HPV testing is likely to improve screening access to a wider female population.
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
HealthEquity (HQY) completes the acquisition of Conduent's BenefitWallet HSA portfolio. This is likely to further strengthen the HSA business of HealthEquity.
Encompass Health (EHC) remains well-poised for growth on the back of robust demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.
In the United States, Align Technology (ALGN) is focused on reaching young adults as well as teens and their parents through famous athletes, influencers and fashion designers.
Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.
Profound Medical's (PROF) Contouring Assistant integrates AI into prostate cancer procedures, thereby streamlining the treatment planning process and enhancing both efficiency and precision.
Thermo Fisher's (TMO) new Applied Biosystems Axiom BloodGenomiX Array and Software provide a high-throughput solution for more precise blood matching research.
medical: Archive
Veeva's (VEEV) Vault Basics to Boost Efficiency for Biotechs
by Zacks Equity Research
Veeva (VEEV) announces the availability of Vault Basics for biotechs, which aims to deliver complete and pre-validated solutions for expanding businesses.
BSXPositive Net Change ECLPositive Net Change ALGNNegative Net Change VEEVPositive Net Change
medical medical-devices
AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft
by Zacks Equity Research
AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.
BSXPositive Net Change ECLPositive Net Change ALGNNegative Net Change AXGNPositive Net Change
medical medical-devices
BD's (BDX) FDA-Approved Test to Offer Wider Testing Access
by Zacks Equity Research
BD's (BDX) receipt of the FDA's clearance for the use of self-collected vaginal specimens for HPV testing is likely to improve screening access to a wider female population.
ECLPositive Net Change BDXNegative Net Change DVAPositive Net Change VEEVPositive Net Change
medical medical-devices
Here's Why Incyte (INCY) Stock is Up More Than 7% in a Week
by Zacks Equity Research
Incyte (INCY) rises 7% in a week as investors appreciated the company's buyback plan to boost returns.
INCYPositive Net Change LGNDPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
Haemonetics' (HAE) Hospital & Plasma Segments, Innovation Aid
by Zacks Equity Research
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
RMDNegative Net Change HAEPositive Net Change MEDPPositive Net Change EHCPositive Net Change
medical
Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control
by Zacks Equity Research
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
LLYNegative Net Change LGNDPositive Net Change ANIPNegative Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Maravai (MRVI) Advances in RNA Research With New Collaboration
by Zacks Equity Research
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
RMDNegative Net Change MEDPPositive Net Change EHCPositive Net Change MRVIPositive Net Change
medical
Haemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.
RMDNegative Net Change HAEPositive Net Change MEDPPositive Net Change EHCPositive Net Change
medical medical-devices
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
by Zacks Equity Research
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
BIIBPositive Net Change LGNDPositive Net Change HRTXNegative Net Change IONSNegative Net Change
biotechs medical pharmaceuticals
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
by Sundeep Ganoria
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
RHHBYPositive Net Change AMGNNegative Net Change ALTNegative Net Change VKTXNegative Net Change NVONegative Net Change LLYNegative Net Change
biotechs medical pharmaceuticals
Tandem Diabetes (TNDM) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Tandem Diabetes (TNDM) outperforms the industry, owing to its impressive series of product launches and an impressive quarterly performance.
CAHPositive Net Change TNDMPositive Net Change MEDPPositive Net Change HITINegative Net Change
medical medical-devices
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
DVAPositive Net Change ALGNNegative Net Change ALCNegative Net Change DXCMNegative Net Change
medical medical-devices
New Strong Buy Stocks for May 17th
by Zacks Equity Research
CLS, DXPE, FBP, RCMT and SIGA have been added to the Zacks Rank #1 (Strong Buy) List on May 17, 2024.
CLSNegative Net Change DXPEPositive Net Change SIGANegative Net Change FBPPositive Net Change RCMTPositive Net Change
business-services computers finance industrial-products medical
Butterfly Network (BFLY) Unveils iQ+ Bladder Ultrasound Scanner
by Zacks Equity Research
Butterfly Network (BFLY) uses proprietary Ultrasound-on-Chip technology to streamline the bladder scanning process.
DVAPositive Net Change ALGNNegative Net Change MEDPPositive Net Change BFLYPositive Net Change
medical medical-devices
Three Reasons to Retain AMN Healthcare (AMN) Stock for Now
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
ECLPositive Net Change DVAPositive Net Change AMNNegative Net Change VEEVPositive Net Change
medical medical-devices
HealthEquity (HQY) Closes Conduent's BenefitWallet Acquisition
by Zacks Equity Research
HealthEquity (HQY) completes the acquisition of Conduent's BenefitWallet HSA portfolio. This is likely to further strengthen the HSA business of HealthEquity.
BSXPositive Net Change ECLPositive Net Change ALGNNegative Net Change HQYPositive Net Change
medical medical-devices
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.
LGNDPositive Net Change ANIPNegative Net Change KODNegative Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
by Ekta Bagri
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
SNYNegative Net Change BMYNegative Net Change MRNAPositive Net Change NVAXNegative Net Change FULCNegative Net Change
biotechnology medical pharmaceuticals
Why You Should Add Encompass Health (EHC) to Your Portfolio Now
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of robust demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.
LGNDPositive Net Change LMATPositive Net Change EHCPositive Net Change OGNPositive Net Change
medical
Align Technology (ALGN) Gains From Innovation, Global Expansion
by Zacks Equity Research
In the United States, Align Technology (ALGN) is focused on reaching young adults as well as teens and their parents through famous athletes, influencers and fashion designers.
ALGNNegative Net Change RMDNegative Net Change MEDPPositive Net Change EHCPositive Net Change
medical
Prestige Consumer (PBH) Q4 Earnings Miss, Operating Margin Falls
by Zacks Equity Research
Prestige Consumer's (PBH) Q4 business suffers from supply chain pressure that impacts its ability to fulfill retailer orders.
RMDNegative Net Change PBHNegative Net Change MEDPPositive Net Change EHCPositive Net Change
earnings medical
Labcorp (LH) to Assess Preeclampsia Risk With New Test
by Zacks Equity Research
Labcorp's (LH) new first-trimester test is the latest addition to its dedication to improving women's health.
LHNegative Net Change RMDNegative Net Change MEDPPositive Net Change EHCPositive Net Change
medical medical-devices
Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data
by Zacks Equity Research
Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.
RHHBYPositive Net Change NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change
biotechs medical pharmaceuticals
Profound Medical (PROF) Adds AI to Prostate Cancer Treatment
by Zacks Equity Research
Profound Medical's (PROF) Contouring Assistant integrates AI into prostate cancer procedures, thereby streamlining the treatment planning process and enhancing both efficiency and precision.
DVAPositive Net Change ALGNNegative Net Change MEDPPositive Net Change PROFNegative Net Change
medical medical-devices
Thermo Fisher (TMO) Unveils New Extended Blood Genotyping Array
by Zacks Equity Research
Thermo Fisher's (TMO) new Applied Biosystems Axiom BloodGenomiX Array and Software provide a high-throughput solution for more precise blood matching research.
TMONegative Net Change MEDPPositive Net Change HIMSPositive Net Change HITINegative Net Change
medical medical-devices